US EditionTraws Pharma Receives Approval to Launch Phase 2 Trials for Ritonavir-Free COVID Treatment
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Traws Pharma Receives Approval to Launch Phase 2 Trials for Ritonavir-Free COVID Treatment
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) announced it has received approval from the Human Research Ethics Committee (HREC) to begin Phase 2 clinical trials of ratutrelvir, a ritonavir-free antiviral candidate for the treatment of COVID-19 in newly diagnosed patients. The studies aim to evaluate ratutrelvir’s safety and efficacy compared to PAXLOVID®, the current standard of care, as well as its potential benefits for patients who cannot …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
